US EditionAbelZeta Announces Remaining China Rights to GPC3 Armored CAR-T Therapy to be Acquired by AstraZeneca
- AbelZeta Pharma announced that AstraZeneca will acquire its 50% share of the China rights to C-CAR031, giving AstraZeneca sole global rights to the therapy.
- AstraZeneca will pay AbelZeta up to $630 million, including an upfront payment and milestone payments for the GPC3 program in China.
- C-CAR031 is a CAR-T therapy targeting Glypican 3 and is being investigated for treating Hepatocellular carcinoma and other solid tumors.
- AstraZeneca previously held the rights to develop C-CAR031 outside of China, and AbelZeta can earn additional milestone payments and royalties for rest of world development.
54 Articles
54 Articles
Chatham Star Tribune
AbelZeta Announces Remaining China Rights to GPC3 Armored CAR-T Therapy to be Acquired by AstraZeneca
ROCKVILLE, Md. and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, announced that AstraZeneca has agreed to acquire AbelZeta's 50%…
AstraZeneca to Acquire AbelZeta’s China Rights to C-CAR031 in Up to $630M Deal
AbelZeta Pharma, Inc., a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, announced that AstraZeneca has agreed to acquire AbelZeta’s 50% share of the China development and commercialization rights to C-CAR031, such that AstraZeneca acquires the sole right to develop, manufacture and commercialize C-CAR031 globally. Under the terms of the agree…
Coverage Details
Bias Distribution
- 73% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
